# US 2023/0257423 A1 · Compositions for treating epithelial barrier function disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0257423 A1
- Document ID: US20230257423A1
- Status: Published application
- Kind: A1
- Application number: 17/794,562
- Filed: 2021-01-22
- Published: 2023-08-17
- Earliest claimed: 2020-01-23
- Applicants: Enterome; Institut National de recherche pour I'agriculture, I'alimentation et I'environnement
- Inventors: Malgorzata NEPELSKA; Joel DORE; Herve BLOTTIERE; Antonella CULTRONE; Christophe BONNY
- Web page: https://patentgrep.com/patent/US20230257423A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07K 9/005: {containing within the molecule the substructure [IMAGE cpc-sch-C07K-1009.gif] with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- C07K 14/195: from bacteria
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to novel pharmaceutical compositions comprising recombinantly engineered probiotic bacteria that can be used, inter alia, in the treatment of gastrointestinal inflammatory diseases and epithelial barrier function disorders. The probiotic bacteria preferably contain a nucleic acid encoding the heterodimeric protein of SEQ ID NO:1 and 2, or homologous sequences thereof sharing at least 80% identity with said sequences. In some embodiments, the pharmaceutical compositions described herein have particular application in the treatment or prevention of disease states associated with abnormally permeable epithelial barriers as well as inflammatory bowel diseases or disorders.

## Claims

### Claim 1

A recombinant nucleic acid encoding a heterodimeric protein comprising a first polypeptide whose amino acid sequence is SEQ ID NO: 1 or a homologous sequence thereof having the same biological function, and a second polypeptide whose amino acid sequence is SEQ ID NO: 2 or a homologous sequence thereof having the same biological function.

### Claim 2 (depends on 1)

The recombinant nucleic acid of claim 1, encoding a heterodimeric protein whose first and second polypeptides have a sequence having at least 80% sequence identity with SEQ ID NO:1 and SEQ ID NO:2 respectively.

### Claim 3 (depends on 1)

The recombinant nucleic acid of claim 1, comprising a first polynucleotide having the sequence SEQ ID NO:3 and a second polynucleotide having the sequence SEQ ID NO:4, or homologous sequences thereof, in the same Open Reading Frame.

### Claim 4 (depends on 1)

The recombinant nucleic acid of claim 1, comprising the polynucleotide having the sequence SEQ ID NO:8, or an homologous thereof sharing at least 80% identity with said sequence and having the same biological function.

### Claim 5 (depends on 1)

The recombinant nucleic acid of claim 1, comprising the polynucleotide having the sequence SEQ ID NO:5, or an homologous thereof sharing at least 80% identity with said sequence and having the same biological function.

### Claim 6 (depends on 3)

The recombinant nucleic acid of claim 3, wherein said first and second polynucleotides are operably linked to regulatory sequences allowing their expression in a host cell.

### Claim 7 (depends on 1)

An expression vector or cassette comprising the recombinant nucleic acid as defined in claim 1.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

A recombinant host cell, comprising the expression vector or cassette of claim 7.

### Claim 10 (depends on 9)

The recombinant host cell of claim 9, comprising a polynucleotide having the sequence SEQ ID NO:5 a polynucleotide having the SEQ ID NO:8.

### Claim 11 (depends on 9)

The recombinant host cell of claim 9, wherein it is a genetically engineered prokaryotic bacterium.

### Claim 12 (depends on 11)

The recombinant host cell of claim 11, wherein it is a non-pathogenic bacteria chosen from the group consisting of: Bacillus, Bacteroides, Bifidobacterium, Brevibacteria, Clostridium, Enterococcus, Escherichia coli, Lactobacillus, Lactococcus and Saccharomyces, e.g., Bacillus coagulans, Bacillus subtilis, Bacteroides fragilis, Bacteroides subtilis, Bacteroides thetaiotaomicron, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, Clostridium butyricum, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactococcus lactis, and Saccharomyces boulardii.

### Claim 13 (depends on 11)

The recombinant host cell of claim 11, wherein it is a Gram-negative non-pathogenic bacterium.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

A pharmaceutical composition comprising the recombinant host cell of claim 11 and a pharmaceutically acceptable carrier.

### Claim 16

A pharmaceutical composition comprising at least one muropeptide chosen from the group consisting of:
and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 8)

A method for:
reducing gastrointestinal inflammation,
reducing intestinal mucosal inflammation,
increasing wound healing,
increasing intestinal epithelial cell proliferation, or for
treating or preventing epithelial barrier function disorders,
said method comprising the step of administering the recombinant host cell of any of claim 8 to a patient in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said epithelial barrier function disorder is chosen in the group consisting of: inflammatory bowel disease, ulcerative colitis, pediatric UC, Crohn's disease, pediatric Crohn's disease, short bowel syndrome, mucositis GI mucositis, oral mucositis, mucositis of the esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (colon), and/or rectum, chemotherapy-induced mucositis, radiation-induced mucositis, necrotizing enterocolitis, pouchitis, a metabolic disease, celiac disease, irritable bowel syndrome, or chemotherapy associated steatohepatitis (CASH).

### Claim 19

(canceled)

### Claim 20

A recombinant heterodimeric protein comprising a first polypeptide whose amino acid sequence is SEQ ID NO: 1, and a second polypeptide whose amino acid sequence is SEQ ID NO: 2, or homologous sequences thereof sharing at least 80% identity with said sequences and having the same biological function.

### Claim 21 (depends on 20)

The recombinant heterodimeric protein of claim 20, comprising the amino acid sequence of SEQ ID NO:9 or a homologous sequence thereof sharing at least 80% identity with SEQ ID NO:9 and having the same biological function.

### Claim 22 (depends on 16, 20)

The recombinant heterodimeric protein of claim 20, wherein said biological function is measured by analysing the presence of the muropeptides as defined in claim 16 in the supernatant of cells overexpressing said recombinant heterodimeric protein.

### Claim 23 (depends on 20)

The recombinant heterodimeric protein of claim 20, wherein said biological function is measured by contacting the supernatant of cells overexpressing said heterodimeric protein with dendritic cells, and observing the upregulation of IL-genes in said cells, or the secretion of IL-10 by said cells.
